Graham Dixon
Chief Tech/Sci/R&D Officer at MITHRA PHARMACEUTICALS S.A.
Network origin in Graham Dixon first degree
| Entity | Entity type | Industry | |
|---|---|---|---|
| Public Company | Pharmaceuticals: Major | 63 | |
| Public Company | Pharmaceuticals: Major | 28 | |
| Public Company | Biotechnology | 26 | |
20
| Public Company | Biotechnology | 20 |
InteRNA Technologies BV
 InteRNA Technologies BV BiotechnologyHealth Technology InteRNA Technologies BV develops RNA technologies and applications. It provides drug discovery and development services for the treatment of cancer based on the proprietary microRNA (miRNA) functions. The company develops miRNA-based therapeutics that control genes connected in signal transduction pathways and biological processes as a part of cancer initiation, progression and metastasis. InteRNA Technologies was founded by Edwin Cuppen and Eugene Berezikov in December 2006 and is headquartered in Nijmegen, the Netherlands.
9
| Holding Company | Biotechnology | 9 |
| Public Company | Pharmaceuticals: Major | 8 | |
Zeneca Garden Care
 Zeneca Garden Care Pharmaceuticals: OtherHealth Technology Part of AstraZeneca PLC, Zeneca Garden Care is a British company that develops and manufactures pharmaceutical products, agrochemicals, and specialty chemicals. The company is based in Macclesfield, UK. Zeneca Garden Care was acquired by Zeneca Group Plc on January 01, 1995 for $84.16 million.
5
| Subsidiary | Pharmaceuticals: Other | 5 |
HepaRegeniX GmbH
 HepaRegeniX GmbH Miscellaneous Commercial ServicesCommercial Services HepaRegeniX GmbH engages in the development of treatment for acute and chronic liver diseases. It focuses on Mitogen-Activated Protein Kinase 4, which unlocks the regenerative capacity of hepatocytes even in severely diseased livers. The company was founded in by Wolfgang Albrecht in 2017 and is headquartered in Tuebingen, Germany.
4
| Holding Company | Miscellaneous Commercial Services | 4 |
Apaxen SA
 Apaxen SA BiotechnologyHealth Technology Apaxen SA is a privately-held biotechnology company that was founded in 2018 and is based in an undisclosed location. The Belgian company has raised €5.4 million in equity and grant funding since its A round in 2019. Apaxen is focused on developing a pipeline of NLRP3 inflammasome inhibitors with a novel mechanism of action for the treatment of chronic inflammatory and autoimmune diseases. The company's clinical candidate, MFC-1040, is an orally bioavailable and selective small molecule NLRP3 inflammasome inhibitor that has demonstrated efficacy in multiple animal models of chronic inflammatory disease and pulmonary fibrosis. The company's team combines the experience required for clinical development of its products and is supported by a world-class team of scientific advisors. Apaxen has a pipeline of products at discovery and preclinical stages of development for the treatment of diseases associated with chronic inflammation that depend on NLRP3 inflammasome activation. The company was founded in 2018 by Gael Jalce, Enrico Jose Adolfo Bastianelli, and Bart Wuurman has been the CEO of the company since 2020.
3
| Holding Company | Biotechnology | 3 |
F2G Ltd.
 F2G Ltd. Pharmaceuticals: MajorHealth Technology F2G Ltd. provides novel drugs for the treatment of life-threatening systemic fungal diseases. It primarily focuses on developing an F3 series of anti mould compound, which is an antifungal agent that acts through a mechanism different from marketed drugs. The company was founded in 1998 and is headquartered in Manchester, the United Kingdom.
2
| Holding Company | Pharmaceuticals: Major | 2 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Graham Dixon via their personal network
| Company | Sector | Related people | Main position |
|---|---|---|---|
AstraZeneca AB
 AstraZeneca AB Miscellaneous Commercial ServicesCommercial Services AstraZeneca AB engages in biopharmaceutical business. It provides treatment of diseases in cardiovascular and metabolic diseases, cancer, respiratory, inflammation, and autoimmunity. The firm offers operations in the areas of infection, neuroscience, and stomach and intestinal diseases. The company was founded in 1999 and is headquartered in Sodertalje, Sweden. | Miscellaneous Commercial Services | Chief Executive Officer Chief Tech/Sci/R&D Officer Chief Executive Officer Director of Finance/CFO Chief Tech/Sci/R&D Officer Corporate Officer/Principal Corporate Officer/Principal | |
| University of Lund | College/University | Doctorate Degree Undergraduate Degree Graduate Degree Undergraduate Degree Corporate Officer/Principal Masters Business Admin Doctorate Degree | |
Atlas Therapeutics AB
 Atlas Therapeutics AB Pharmaceuticals: MajorHealth Technology Part of Alligator Bioscience AB, Atlas Therapeutics AB develops and manufactures antibody drugs. The company is based in Stockholm, Sweden. Atlas Therapeutics was acquired by Alligator Bioscience AB on October 18, 2013. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Chairman Director/Board Member Director/Board Member Chairman | |
| University of Liege | College/University | Corporate Officer/Principal Doctorate Degree Graduate Degree Corporate Officer/Principal Masters Business Admin Undergraduate Degree | |
| Katholieke Universiteit Leuven | College/University | Graduate Degree Doctorate Degree Doctorate Degree Graduate Degree Graduate Degree | |
| A Bioscience Incentive AB | Chairman Chairman Director/Board Member Director/Board Member | ||
Royal Swedish Academy of Engineering Sciences
 Royal Swedish Academy of Engineering Sciences Miscellaneous Commercial ServicesCommercial Services The Royal Swedish Academy of Engineering Sciences (IVA) is an organization that brings together around 1,300 academy members and 250 companies to bridge the gap between academia, business, and politics. The non-profit company is based in Stockholm, Sweden. The Swedish company's aim is to work towards people's ability to contribute positively to society. The organization runs an internship program called Tekniksprånget, which gives young people in Sweden the opportunity to test the engineering profession through a four-month paid internship. The program has been running since 2012 and aims to inspire more people to choose a higher technical education. The CEO of the company is Björn O. Nilsson. | Miscellaneous Commercial Services | Corporate Officer/Principal Chairman Director/Board Member Corporate Officer/Principal | |
| University of Utrecht | College/University | Doctorate Degree Doctorate Degree Graduate Degree Corporate Officer/Principal | |
| University of Uppsala | College/University | Doctorate Degree Graduate Degree Doctorate Degree Corporate Officer/Principal | |
| SHIRE | Pharmaceuticals: Major | Director/Board Member Chief Executive Officer General Counsel Corporate Officer/Principal | |
| BIOINVENT INTERNATIONAL AB | Biotechnology | Founder Investor Relations Contact Director/Board Member Director/Board Member | |
| ZEALAND PHARMA A/S | Pharmaceuticals: Major | Director/Board Member Chairman Director/Board Member Director/Board Member | |
| BIOCARTIS GROUP NV | Medical Specialties | Director/Board Member Director/Board Member Chief Executive Officer | |
Oblique Therapeutics AB
 Oblique Therapeutics AB Pharmaceuticals: MajorHealth Technology Oblique Therapeutics AB is a privately held Swedish biotech company that develops innovative new medicines for severe diseases with a large unmet medical need, focusing on pain and advanced cancer. The company is based in Gothenburg, Sweden. The company uses abiprot®, an in-house-invented, next-generation antibody platform that can generate antibodies with programmed function against the full human proteome. The portfolio comprises several antibody candidates and the small molecule ot-1096 in triple-negative breast cancer. In addition, two antibody programs are run in R&D collaborations with pharma companies. The company was founded in 2015 by Jan Owe Owesson Orwar, and Christer Nordstedt has been the CEO of the company since 2022. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Director/Board Member | |
Pharmaceutical Research & Manufacturers of America
 Pharmaceutical Research & Manufacturers of America Pharmaceuticals: MajorHealth Technology Pharmaceutical Research & Manufacturers of America provides pharmaceutical research and biotechnology services. It represents the country’s biopharmaceutical research companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier, and more productive lives. The company was founded in 1958 and is headquartered Washington, DC. | Pharmaceuticals: Major | Chairman Chairman Corporate Officer/Principal | |
| Université Catholique de Louvain | College/University | Doctorate Degree Doctorate Degree Undergraduate Degree | |
| Karolinska Institutet | College/University | Corporate Officer/Principal Doctorate Degree Doctorate Degree | |
Uteron Pharma SA
 Uteron Pharma SA Electronic Equipment/InstrumentsElectronic Technology Uteron Pharma SA is engaged in the research and development of controlled release devices. The firms products Levosert and Diafert provide pharmaceutical solutions for women's health. The company was founded by Stijn van Rompay in 2010 and is headquartered in Grâce-Hollogne, Belgium. | Electronic Equipment/Instruments | Founder Director/Board Member Founder | |
| IMMUNOVIA AB | Pharmaceuticals: Major | Founder Director/Board Member Investor Relations Contact | |
European Federation of Pharmaceutical Industries & Assns
 European Federation of Pharmaceutical Industries & Assns Miscellaneous Commercial ServicesCommercial Services The European Federation of Pharmaceutical Industries & Assns is a trade association that promotes pharmaceutical discovery and development. The non-profit company is based in Brussels, Belgium. | Miscellaneous Commercial Services | President Director/Board Member Director/Board Member | |
| IRLAB THERAPEUTICS AB | Pharmaceuticals: Major | Director/Board Member Director/Board Member Director/Board Member | |
| DICOT PHARMA AB | Pharmaceuticals: Major | Chairman Director/Board Member Investor Relations Contact | |
EUSA Pharma, Inc.
 EUSA Pharma, Inc. Pharmaceuticals: MajorHealth Technology EUSA Pharma is a rapidly growing transatlantic specialty pharmaceutical company focused on in-licensing, developing and marketing late-stage oncology, pain control and critical care products. The company currently has eight products on the market, including Caphosol for the treatment of oral mucositis, a common and debilitating side-effect of radiation therapy and high-dose chemotherapy, ProstaScint for imaging the extent and spread of prostate cancer, Quadramet for the treatment of pain in patients whose cancer has spread to the bones, Erwinase and Kidrolase for the treatment of acute lymphoblastic leukemia and the antibiotic surgical implant Collatamp. EUSA also has several products in late-stage development, notably Collatamp topical, a gentamicin impregnated collagen sponge for the prevention and treatment of infected skin ulcers, and CollaRx bupivacaine implant for local post-surgical pain control. Founded in 2006, EUSA Pharma is supported by a consortium of leading life science capital investors, comprising TVM Capital, Essex Woodlands, 3i, Goldman Sachs, Advent Venture Partners, SV Life Sciences, NeoMed and NovaQuest. Since its foundation, the company has raised over $275 million, and completed several significant transactions, including the acquisitions of Cytogen Corporation, Talisker Pharma Ltd, the French biopharmaceutical company OPi SA and the European antibiotic and pain control business of Innocoll Pharmaceuticals Inc. As part of its rapid growth strategy the company has established commercial infrastructure in the US, a pan-European presence covering over 20 countries and a wider distribution network in a further 25 territories. EUSA Pharma plans to continue its aggressive program of acquisitions and in-licensing within its specialist areas of medical and geographic focus, in line with its ambitious target to create a rapidly growing $1 billion company by the beginning of the next decade. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| STORYTEL AB | Publishing: Books/Magazines | Director/Board Member Director/Board Member | |
| ELI LILLY AND COMPANY | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Chief Tech/Sci/R&D Officer | |
| BEKAERT NV | Metal Fabrication | Director of Finance/CFO Director of Finance/CFO | |
Biotechnology Innovation Organization
 Biotechnology Innovation Organization Miscellaneous Commercial ServicesCommercial Services Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
| Swedish Academy For Pharmaceutical Sciences | Corporate Officer/Principal Chairman | ||
| BioCrine AB | Chairman Director/Board Member | ||
| Handelshögskolan i Göteborg | College/University | Masters Business Admin Graduate Degree | |
Theravectys SAS
 Theravectys SAS BiotechnologyHealth Technology Theravectys SAS provides biotechnology research services. It is working on the development of a therapeutic vaccine against HIV. The company was founded on May 17, 2005 and is headquartered in Paris, France. | Biotechnology | Chairman Director/Board Member | |
| Radboud University Nijmegen | College/University | Doctorate Degree Doctorate Degree | |
| REPARE THERAPEUTICS INC. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Chief Tech/Sci/R&D Officer | |
| CMC SPV of 3 April 2017 AB | Director/Board Member Director/Board Member | ||
| University of Oxford | College/University | Corporate Officer/Principal Corporate Officer/Principal | |
| University of Gothenburg | College/University | Doctorate Degree Graduate Degree | |
| SWEDISH ORPHAN BIOVITRUM AB | Pharmaceuticals: Major | Chief Executive Officer Director/Board Member | |
| THERAVET SA | Miscellaneous Commercial Services | Chairman Director/Board Member | |
Biocartis SA
 Biocartis SA Medical SpecialtiesHealth Technology Biocartis SA develops molecular diagnostic solutions. It focuses on Oncology. The firm’s products include Idylla and Oncology assays and mutation tests. It also provides instant access to personalized medicine for patients. The company was founded by Rudi Pauwels in 2007 and is headquartered in Lausanne, Switzerland. | Medical Specialties | Director/Board Member Chief Executive Officer | |
| CELYAD ONCOLOGY SA | Biotechnology | Founder Director/Board Member | |
| NYKODE THERAPEUTICS | Pharmaceuticals: Major | Chairman Director/Board Member | |
AnaMar AB
 AnaMar AB Pharmaceuticals: MajorHealth Technology AnaMar AB develops drugs and provides research services for chronic joint diseases. It focuses on the discovery, development and commercialization of novel therapeutic strategies to treat debilitating inflammation and pain. The company was founded in 1998 and is headquartered in Lund, Sweden. | Pharmaceuticals: Major | Chairman Corporate Officer/Principal | |
| PFIZER, INC. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
| Vlerick Leuven Gent Management School | College/University | General Counsel Masters Business Admin |
Statistics
International
| Sweden | 23 |
| Belgium | 11 |
| United States | 6 |
| Netherlands | 4 |
| Canada | 3 |
Sectoral
| Health Technology | 24 |
| Consumer Services | 14 |
| Commercial Services | 8 |
| Electronic Technology | 2 |
| Producer Manufacturing | 2 |
Operational
| Director/Board Member | 655 |
| Corporate Officer/Principal | 204 |
| Independent Dir/Board Member | 159 |
| Chairman | 155 |
| Chief Executive Officer | 112 |
Most connected contacts
- Stock Market
- Insiders
- Graham Dixon
- Company connections
